Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Sarcoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 59Cisplatin 45Cetuximab 29Radiotherapy 26Carboplatin 24Docetaxel 17Paclitaxel 16Nivolumab 16Surveys and Questionnaires 15Radiotherapy, Intensity-Modulated 13Fluorouracil 12Drug Therapy 12Blood Specimen Collection 11Standard of Care 8tislelizumab 7cemiplimab 6atezolizumab 6Radiation 6Chemoradiotherapy 6toripalimab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5nimotuzumab 4fludarabine 4durvalumab 4dostarlimab 4Surgical Procedures, Operative 4Afatinib 4palbociclib 3niraparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Interleukin-15 × 1 year × Clear all
NCT06239220 2026-02-27

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
25 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡